Roughly 90% of adults worldwide carry Epstein-Barr virus, making it one of the most common human infections on the planet. In real numbers, that translates to well over 5 billion people. Most were infected during childhood, never knew it, and now carry the virus for life.
Global and U.S. Prevalence by Age
EBV spreads primarily through saliva, which is why it picks up most of its hosts early in life. In the United States, nationally representative data from 2003 to 2010 show that about 50% of children are already infected by ages 6 to 8. That number climbs steadily: 59% by ages 12 to 14, 69% by ages 15 to 17, and 89% by ages 18 to 19. By age 35, more than 90% of people carry detectable antibodies.
Infection rates vary across demographic groups. U.S. data show seroprevalence of 85.4% among Mexican-Americans and 83.1% among non-Hispanic Black children and adolescents, compared to 56.9% among non-Hispanic whites in the same age range. Girls and women also test positive at slightly higher rates than boys and men (about 69% versus 64% in the 6 to 19 age group). These differences likely reflect household size, childcare patterns, and other social factors that affect how early children share saliva through cups, utensils, or close contact.
Interestingly, the overall rate among U.S. children appears to be declining. Age-adjusted prevalence dropped from 72% in 2003–2004 to 65% in 2009–2010. Smaller household sizes and improved hygiene may be pushing first infections later into adolescence and young adulthood, which has its own consequences.
Why Most People Never Know They Have It
When young children catch EBV, the infection is almost always silent. There’s no fever, no sore throat, no reason to test. The virus quietly sets up permanent residence in a type of white blood cell and stays there indefinitely. This is why so many adults test positive without any memory of being sick.
The story changes when infection happens later. Among teenagers and young adults who catch EBV for the first time, roughly 30% to 50% develop infectious mononucleosis, the illness known as “mono.” Some estimates put that figure as high as 74% in certain populations. Mono brings weeks of fatigue, swollen lymph nodes, sore throat, and sometimes an enlarged spleen. Each year, 10% to 20% of people who haven’t yet been exposed to EBV become newly infected.
The Virus Stays Active After Recovery
Once you carry EBV, you carry it permanently. The virus persists in a dormant state inside immune cells but periodically reactivates and sheds into saliva. Research tracking eight EBV-positive individuals over time found that all of them were continuously shedding virus, with only 8 out of 173 saliva samples coming back negative. The saliva reservoir of virus gets completely replaced roughly every two minutes. Broader studies estimate that anywhere from 10% to 70% of healthy carriers have detectable virus in their saliva at any given time, depending on the sensitivity of the test used.
This constant, invisible shedding is exactly why EBV is so widespread. You don’t need to be sick to pass it on. Sharing a drink, kissing, or any routine saliva contact can transmit the virus from someone who feels perfectly fine.
Health Risks Linked to EBV
For the vast majority of carriers, EBV causes no ongoing problems. But the virus has a well-documented connection to several serious conditions. The International Agency for Research on Cancer estimates that EBV-related cancers, including certain lymphomas, nasopharyngeal carcinoma, and about 10% of stomach cancers, account for 240,000 to 358,000 new cancer cases globally each year and 138,000 to 209,000 cancer deaths. Burkitt lymphoma, a fast-growing cancer most common in sub-Saharan Africa, is the most well-known EBV-linked malignancy.
The connection to multiple sclerosis has drawn particular attention. A landmark study tracking over 10 million active-duty U.S. military personnel over 20 years identified 801 MS cases. EBV infection was present in all but one case at the time of MS onset. Among 35 individuals who were initially EBV-negative, 34 became infected before developing MS. This doesn’t mean EBV causes MS in everyone who carries it, but it strongly suggests the virus is a necessary precursor in nearly all cases.
How Infection Is Confirmed
Blood tests detect antibodies your immune system produces in response to different parts of the virus, and the pattern of those antibodies tells your doctor whether you’ve been recently infected or carried the virus for months or years.
A new or recent infection shows one pattern: antibodies against the viral capsid (the virus’s outer shell) appear early, with a specific short-lived type that typically disappears within four to six weeks. At this stage, antibodies against a protein found inside the virus’s nucleus are absent. They develop slowly over two to four months and then persist for life.
A past infection looks different. Both types of antibodies are present simultaneously. If your blood shows this combination, you were infected months to years ago. Most adults who get tested will show this past-infection pattern, confirming what the statistics predict: chances are, you already have it.
No Vaccine Yet
Despite infecting the overwhelming majority of humanity and contributing to hundreds of thousands of cancer cases each year, there is no approved vaccine for EBV. A phase I clinical trial has tested a nanoparticle-based vaccine targeting a protein on the virus’s surface, and early results focus on safety and whether the vaccine triggers neutralizing antibodies. This is the first step in a long development process, and an approved vaccine remains years away at best.